DK1401869T3 - Molekyler og fremgangsmåder til inhibering af udskillkelse af kim 1 - Google Patents

Molekyler og fremgangsmåder til inhibering af udskillkelse af kim 1

Info

Publication number
DK1401869T3
DK1401869T3 DK02734634T DK02734634T DK1401869T3 DK 1401869 T3 DK1401869 T3 DK 1401869T3 DK 02734634 T DK02734634 T DK 02734634T DK 02734634 T DK02734634 T DK 02734634T DK 1401869 T3 DK1401869 T3 DK 1401869T3
Authority
DK
Denmark
Prior art keywords
methods
excretion
molecules
inhibiting germ
kim
Prior art date
Application number
DK02734634T
Other languages
Danish (da)
English (en)
Inventor
Veronique Bailly
Joseph Bonventre
Original Assignee
Biogen Idec Inc
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc, Gen Hospital Corp filed Critical Biogen Idec Inc
Application granted granted Critical
Publication of DK1401869T3 publication Critical patent/DK1401869T3/da

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854Immunoglobulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/02Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK02734634T 2001-06-01 2002-05-31 Molekyler og fremgangsmåder til inhibering af udskillkelse af kim 1 DK1401869T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29544901P 2001-06-01 2001-06-01
US29590701P 2001-06-04 2001-06-04
PCT/US2002/017402 WO2002098920A1 (en) 2001-06-01 2002-05-31 Molecules and methods for inhibiting shedding of kim-1

Publications (1)

Publication Number Publication Date
DK1401869T3 true DK1401869T3 (da) 2008-04-28

Family

ID=26969139

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02734634T DK1401869T3 (da) 2001-06-01 2002-05-31 Molekyler og fremgangsmåder til inhibering af udskillkelse af kim 1

Country Status (10)

Country Link
US (3) US7041290B2 (ru)
EP (1) EP1401869B1 (ru)
JP (2) JP4527394B2 (ru)
AT (1) ATE382060T1 (ru)
AU (1) AU2002305785B2 (ru)
CA (1) CA2448427C (ru)
DE (1) DE60224275T2 (ru)
DK (1) DK1401869T3 (ru)
NZ (1) NZ530457A (ru)
WO (1) WO2002098920A1 (ru)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT907735E (pt) * 1996-05-24 2006-06-30 Biogen Idec Inc Moduladores da regeneracao de tecidos
DE60137934D1 (de) * 2000-06-16 2009-04-23 Biogen Idec Inc Renale regulatorische elemente und deren verwendung
ATE382060T1 (de) * 2001-06-01 2008-01-15 Biogen Idec Inc Moleküle und verfahren zur inhibierung der freisetzung von kim-1
WO2003080856A2 (en) * 2002-03-19 2003-10-02 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
AU2013205381B2 (en) * 2002-03-19 2016-04-14 Celldex Therapeutics, Inc. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2004060041A2 (en) * 2002-12-30 2004-07-22 Biogen Idec Ma Inc. Kim-1 antagonists and use to modulate immune system
AU2013242840B2 (en) * 2003-03-19 2017-01-19 Amgen Fremont Inc. Antibodies Against T Cell Immunoglobulin Domain and Mucin Domain 1 (TIM-1) Antigen and Uses Thereof
EP1613750B1 (en) * 2003-03-19 2015-10-14 Amgen Fremont Inc. Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof
EP1532984A1 (en) * 2003-11-19 2005-05-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of anti CD44 antibodies for eradicating stem cells in acute myeloid leukemia
BRPI0608254A2 (pt) * 2005-03-02 2009-12-08 Biogen Idec Inc anticorpos kim-1 para o tratamento de condições mediadas por th2
CA2629453C (en) 2005-11-10 2018-03-06 Curagen Corporation Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen
PT2894165T (pt) 2008-11-10 2023-03-17 Alexion Pharma Inc Métodos e composições para o tratamento de distúrbios associados ao complemento
JP6199558B2 (ja) 2009-12-23 2017-09-20 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド イヌにおける腎障害を診断し、そして治療するための組成物および方法
MX2012008108A (es) 2010-01-11 2012-10-03 Alexion Pharma Inc Biomarcadores de efectos de inmunomodulacion en seres humanos tratados con anticuerpos anti-cd200.
US9011852B2 (en) 2010-04-30 2015-04-21 Alexion Pharmaceuticals, Inc. Anti-C5a antibodies
AU2012212066A1 (en) 2011-02-03 2013-08-15 Alexion Pharmaceuticals, Inc. Use of an anti-CD200 antibody for prolonging the survival of allografts
WO2013078089A1 (en) * 2011-11-22 2013-05-30 Biogen Idec Ma Inc. Anti-tim-1 antibodies and uses thereof
WO2015023836A1 (en) * 2013-08-16 2015-02-19 The Brigham And Women's Hospital, Inc. Kim-1 as a therapeutic target in conditions associated with kidney fibrosis
US10712349B2 (en) 2014-04-15 2020-07-14 The Brigham And Women's Hospital, Inc. Circulating KIM-1 levels for detection of pathologies associated with injury to, or cancer of, the kidney
JP7303749B2 (ja) * 2017-01-13 2023-07-05 セルダラ メディカル、エルエルシー Tim-1を標的とするキメラ抗原受容体
IL301115A (en) 2017-04-28 2023-05-01 Acuitas Therapeutics Inc New lipid carbonyl and lipid nanoparticle formulations for delivery of nucleic acids
CN113474328A (zh) 2019-01-11 2021-10-01 爱康泰生治疗公司 用于脂质纳米颗粒递送活性剂的脂质
WO2022016070A1 (en) 2020-07-16 2022-01-20 Acuitas Therapeutics, Inc. Cationic lipids for use in lipid nanoparticles

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622861A (en) 1994-08-05 1997-04-22 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA encoding hepatitis A virus receptor
PT907735E (pt) * 1996-05-24 2006-06-30 Biogen Idec Inc Moduladores da regeneracao de tecidos
DE60137934D1 (de) * 2000-06-16 2009-04-23 Biogen Idec Inc Renale regulatorische elemente und deren verwendung
ATE382060T1 (de) * 2001-06-01 2008-01-15 Biogen Idec Inc Moleküle und verfahren zur inhibierung der freisetzung von kim-1
US7838220B2 (en) 2001-06-29 2010-11-23 The Board Of Trustees Of The Leland Stanford Junior University T cell regulatory genes associated with immune disease
US7553939B2 (en) 2001-06-29 2009-06-30 The Board Of Trustees Of The Leland Stanford Junior University T cell regulatory genes and methods of use thereof
WO2003025138A2 (en) 2001-09-17 2003-03-27 Protein Design Labs, Inc. Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
WO2003042661A2 (en) 2001-11-13 2003-05-22 Protein Design Labs, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
US7687454B2 (en) 2001-12-03 2010-03-30 The University Of British Columbia Effectors of innate immunity determination
CA2474497C (en) 2002-01-30 2013-12-03 The Brigham And Women's Hospital, Inc. Compositions and methods related to tim-3, a th1-specific cell surface molecule
WO2003080856A2 (en) 2002-03-19 2003-10-02 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
GB0215509D0 (en) 2002-07-04 2002-08-14 Novartis Ag Marker genes
EP1613750B1 (en) 2003-03-19 2015-10-14 Amgen Fremont Inc. Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof
WO2005001092A2 (en) 2003-05-20 2005-01-06 Wyeth Compositions and methods for diagnosing and treating cancers

Also Published As

Publication number Publication date
AU2002305785B2 (en) 2008-01-17
US20060153836A1 (en) 2006-07-13
US20080124336A1 (en) 2008-05-29
WO2002098920A1 (en) 2002-12-12
US7041290B2 (en) 2006-05-09
DE60224275T2 (de) 2008-12-11
JP2005505256A (ja) 2005-02-24
US7300652B2 (en) 2007-11-27
JP2010150291A (ja) 2010-07-08
EP1401869A4 (en) 2005-10-19
CA2448427A1 (en) 2002-12-12
US7696321B2 (en) 2010-04-13
DE60224275D1 (de) 2008-02-07
NZ530457A (en) 2007-12-21
JP4527394B2 (ja) 2010-08-18
EP1401869B1 (en) 2007-12-26
CA2448427C (en) 2013-09-24
EP1401869A1 (en) 2004-03-31
US20050112117A1 (en) 2005-05-26
ATE382060T1 (de) 2008-01-15

Similar Documents

Publication Publication Date Title
DK1401869T3 (da) Molekyler og fremgangsmåder til inhibering af udskillkelse af kim 1
DK1171417T3 (da) Fremgangsmåde til fremstilling af 3-aryloxy-3-arylpropylaminer og mellemprodukter deraf
DK1211361T3 (da) Momentmodstående stropforbindelse
DK1261368T3 (da) Tværbunden, ikke-fungal lipaseholdig sammensætning og fremgangsmåder til anvendelse deraf
DE69939864D1 (de) Ppar-gamma modulatoren
NO20030856L (no) Membranpenetrerende peptider og anvendelse av disse
DK2258168T3 (da) Apparat til isolering af X-kromosombærende og Y-kromosombærende populationer af spermatozoer
DK1276551T3 (da) Kompositmembran og fremgangsmåde til fremstilling af samme
TR200602095T2 (tr) Hümanize Anti-LT-Beta-R antikorları
DK1372686T3 (da) Fremgangsmåder og sammensætninger til peptidsyntese
DK1553975T3 (da) Optimerede Fc-varianter og fremgangsmåder til generering heraf.
DK1066049T3 (da) Farmaceutiske præparater, der er beregnet til langvarig frigivelse af peptider og fremgangsmåde til fremstilling af disse
DK2322603T3 (da) Sammensætninger og fremgangsmåder til aktivering af monocytiske dendritiske celler og t-celler for th1-respons
DK1437966T3 (da) Måling af proteinsyntesehastigheder hos mennesker og i forsøgssystemer ved anvendelse af isotopisk mærket vand
DK1352895T3 (da) Adamantanderivater til behandling af inflammatioriske immunologiske og kardiovaskulære sygdomme
DE60128652D1 (de) Prostatischer stent zur erleichterung der drainage
MX2007011900A (es) Sistema de celula reproductora.
DK1259593T3 (da) Tand-progenitorcelle og fremgangsmåde til frembringelse heraf
MA30265B1 (fr) Procedes et compositions destines a cibler relt
DE60139893D1 (de) Neue fructosyl-aminosäureoxidase
DK1484056T3 (da) Sammensætninger med langsom frigivelse og fremgangsmåde til fremstilling af disse
DK1392822T3 (da) Dobbelttransficeret cellelinie anvendelig til identifikation af transporthæmmere
DE50113351D1 (de) Zubereitungen enthaltend einen extrakt der pflanze pistia stratiotes
ATE363906T1 (de) Aromatase hemmung zur steigerung der implantationsrate
DE60202757D1 (de) Zweidimensionale pyramidenfilterarchitektur